Stryker invests $400 million in CMR Surgical for exclusive U.S. Versius sales and acquisition option
Stryker announced a preferred‑equity investment of approximately $400 million (£300 million) in CMR Surgical, giving it exclusive rights to sell the Versius soft‑tissue robotic system in the United States. The agreement also includes an exclusive call option for Stryker to acquire 100 % of CMR Surgical’s remaining equity. The deal coincides with the planned transition of Spencer Stiles to CEO on Jan 1 2027 and Andy Pierce joining CMR’s board.
Why it matters
Stryker says the partnership will broaden its robotic portfolio beyond orthopedics and position it to capture growth in the expanding soft‑tissue surgery market. Nelson Advisors notes the move creates a multi‑platform competitive landscape that could shift market share from incumbent Intuitive Surgical.
Key facts
- 1Stryker committed approximately $400 million (£300 million) in preferred equity to CMR Surgical. zacks.com
- 2The transaction grants Stryker exclusive commercial agency rights for the Versius robotic portfolio in the United States. zacks.com
- 3Stryker received an exclusive call option to acquire 100 % of CMR Surgical’s outstanding equity. healthcare.digital
- 4The agreement was announced on October 12 2026. healthcare.digital
- 5Spencer Stiles will become Stryker’s chief executive officer on January 1 2027. healthcare.digital
- 6Andy Pierce, Stryker’s group president of MedSurg and Neurotechnology, will join CMR Surgical’s board. zacks.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.